38 research outputs found
Recommended from our members
NoSQL Database Technologies
As cloud computing continues to evolve, organizations are finding new ways to store the massive amounts of big data that are collected. Big data storage often require greater flexibility and scalability which can be provided by incorporating NoSQL technologies. NoSQL (Not Only SQL) is quickly becoming a popular approach to store large and unstructured data. This paper looks at the various classifications of NoSQL technologies as well as many of the notable characteristics of the technologies. The authors also describe some deficiencies of using NoSQL and give some explanation to why companies are adopting the technology. The paper concludes with suggestions for future research of NoSQL technologies and a content analysis of current articles in database management is provided in the appendix
The Effect of Leucogenenol and Chemotherapy on Leukemia L1210
55 leaves.The problem. This study determined the effect of leucogenenol, an untried immunostimulant, in conjunction with known effective chemotherapy on mouse leukemia L1210.
Procedure. L1210 infected animals in various treatment groups were monitored for changes in several parameters of the disease. Among these parameters were differential smears, hematocrits, total nucleated cell counts, spleen and liver weights to total body weight ratios and survival times.
Findings. Although some of the parameters of the leukemia were decreased after leucogenenol therapy, a minimal detrimental effect was observed in the survival times of the animals. The humoral antibody levels were elevated after leucogenenol and chemotherapeutic treatment, but these were obviously not effective in controlling the number of proliferating L1210 leukemic cells.
Conclusion. It was concluded that leucogenenol was able to increase the humoral antibody response but not the number of sensitized lymphocytes such that the residual leukemic cells could be destroyed immunologically. Hence, even in combination with chemotherapy, leucogenenol's action could not turn the race between the residual leukemic cells and sensitized lymphocytes in favor of the host.
Recommendations. The recent demonstration of immunological enhancement of a tumor by humoral antibodies makes it important to determine if leucogenenol's action is specific for the B lymphoid cells or does it affect both the B and T lymphoid cells? A method for determining the molecular action of leucogenenol might lead to a greater understanding of the control of hematopoiesis and leukemias
Concert recording 2017-11-15
[Track 1]. Fanfare for barcs / Kerry Turner -- [Track 2]. Three for five / James Naigus -- [Track 3]. Big sky country / Daniel Baldwin
Exploration of the Southern California Borderland
E/V Nautilus cruise NA075 returned to the Southern California Continental Borderland, an area that remains largely unexplored. Part of the broader North America-Pacific plate boundary, this region extends ~300 km west of the San Andreas Fault and displays an unusually rugged physiography. During the cruise, the multibeam sonar mapped ~5,200 km2 of seafloor, and ROVs Hercules and Argus were deployed for 16 dives to explore geological and biological targets (Figure 1) and collect samples
From St. Petersburg to Krushchev\u27s Boot
Program for the first annual RISD Cabaret held in Memorial Hall. Design and layout by Justin Kerr.https://digitalcommons.risd.edu/liberalarts_cabaret_programs/1000/thumbnail.jp
Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease
Parkinson disease (PD) is a neurodegenerative disorder particularly
characterized by the loss of dopaminergic neurons in the substantia nigra. Pesticide exposure has been associated with PD occurrence, and
we previously reported that the fungicide benomyl interferes with
several cellular processes potentially relevant to PD pathogenesis.
Here we propose that benomyl, via its bioactivated thiocarbamate
sulfoxide metabolite, inhibits aldehyde dehydrogenase (ALDH), leading
to accumulation of the reactive dopamine metabolite 3,4-dihydroxyphenylacetaldehyde
(DOPAL), preferential degeneration of
dopaminergic neurons, and development of PD. This hypothesis is
supported by multiple lines of evidence. (i) We previously showed
in mice the metabolism of benomyl to S-methyl N-butylthiocarbamate
sulfoxide, which inhibits ALDH at nanomolar levels. We report
here that benomyl exposure in primary mesencephalic neurons (ii)
inhibits ALDH and (iii) alters dopamine homeostasis. It induces selective
dopaminergic neuronal damage (iv) in vitro in primary mesencephalic
cultures and (v) in vivo in a zebrafish system. (vi) In vitro
cell loss was attenuated by reducing DOPAL formation. (vii) In our
epidemiology study, higher exposure to benomyl was associated
with increased PD risk. This ALDH model for PD etiology may help
explain the selective vulnerability of dopaminergic neurons in PD
and provide a potential mechanism through which environmental
toxicants contribute to PD pathogenesis
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years
Paediatric schistosomiasis:What we know and what we need to know
Schistosomiasis affects over 200 million people worldwide, most of whom are children. Research and control strategies directed at preschool-aged children (PSAC), i.e., ≤5 years old, have lagged behind those in older children and adults. With the recent WHO revision of the schistosomiasis treatment guidelines to include PSAC, and the recognition of gaps in our current knowledge on the disease and its treatment in this age group, there is now a concerted effort to address these shortcomings. Global and national schistosome control strategies are yet to include PSAC in treatment schedules. Maximum impact of schistosome treatment programmes will be realised through effective treatment of PSAC. In this review, we (i) discuss the current knowledge on the dynamics and consequences of paediatric schistosomiasis and (ii) identify knowledge and policy gaps relevant to these areas and to the successful control of schistosome infection and disease in this age group. Herein, we highlight risk factors, immune mechanisms, pathology, and optimal timing for screening, diagnosis, and treatment of paediatric schistosomiasis. We also discuss the tools required for treating schistosomiasis in PSAC and strategies for accessing them for treatment
Reconciling Enterprise Security Concerns with the BYOD Trend
Employees increasingly want to use their own mobile devices for work and they have demonstrated that when they can use devices of their choosing for work purposes it increases their morale and consequently augments productivity. At the same time, companies want to ensure that these mobile devices adequately secure corporate data. Companies need to find a balancing point between their security concerns and their employees\u27 expectations of control over their mobile devices. The primary research question for this analysis concerns how enterprises can reconcile their own security concerns with the BYOD trend